🇺🇸 FDA
Patent

US 8299040

Methods for treating cancer targeting transglutaminase

granted A61KA61K48/00A61P

Quick answer

US patent 8299040 (Methods for treating cancer targeting transglutaminase) held by The Board of Regents of the University of Texas System expires Mon Oct 25 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Oct 30 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 25 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K48/00, A61P, A61P31/00